MRD Study 201-21-202 clear bkgd partial color

The MRD Study is enrolling women who are diagnosed with stage 3 or 4 (advanced) ovarian, fallopian tube, or primary peritoneal cancer and are looking for an opportunity to potentially try both the standard of care (chemotherapy, BEV and surgery) treatment plus an investigational immunotherapy treatment.


The MRD Study is evaluating an investigational immunotherapy combined with traditional standard of care (chemotherapy, BEV and surgery) treatment, compared to standard of care treatment alone, in women with newly diagnosed or suspected late-stage ovarian cancer.

*Standard of care treatment — Standard of care, or best practice, is a guideline for the appropriate treatment of a condition, as established by formal or informal consensus among experts on that condition. Basically, the standard of care for the treatment of a disease is whatever most physicians agree is the best way to treat that disease.

Am I Eligible?